Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck amp Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
Quote | Ablynx NV (NASDAQ:ABLX)
Last: | $ |
---|---|
Change Percent: | 0.21% |
Open: | $52.92 |
Close: | $52.87 |
High: | $53.155 |
Low: | $52.80 |
Volume: | 14,581 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Ablynx NV (NASDAQ:ABLX)
Message Board Posts | Ablynx NV (NASDAQ:ABLX)
Subject | By | Source | When |
---|---|---|---|
and still very promising, because $ABLX rejected the proposal | nixke | investorshub | 01/08/2018 8:21:30 PM |
Wow. These are the days I live for... | D_rwc | investorshub | 01/08/2018 2:56:22 PM |
http://www.ablynx.com/ anyone who knows something about this future biotech | nixke | investorshub | 11/20/2017 8:17:24 PM |